Search Results

You are looking at 1 - 10 of 59 items for :

  • "Myeloid growth factors" x
Clear All
Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

Myeloid growth factors (MGFs) are a class of biologic agents that regulate the proliferation, differentiation, survival, and activation of cells in the myeloid lineage. In patients with cancer receiving myelosuppressive chemotherapy, MGFs are primarily

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt and Michael Westmoreland

are lacking on the clinical benefits of G-CSFs and GM-CSFs. NCCN Clinical Practice Guidelines in Oncology : Myeloid Growth Factors Version Version 1.2011, 03-04-11 ©2011 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer and Maria Ho

, vitality, and mental health. 4 NCCN Clinical Practice Guidelines in Oncology : Myeloid Growth Factors, Version 2.2013 Version 2.2013, 08-02-13 ©2013 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines#x000AE; and

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

the express written permission of the NCCN © 2009. Disclosures for the NCCN Myeloid Growth Factors Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from

Full access

Gary H. Lyman and Jessica Malone Kleiner

the National Comprehensive Cancer Network on the use of the myeloid growth factors with cancer chemotherapy: a review of the evidence . J Natl Compr Canc Netw 2005 ; 3 : 557 – 571 . 4. Kuderer NM Dale D Crawford J . The morbidity

Full access

Betsy L. Althaus

The author has no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1. Crawford J Althaus B Armitage J . The NCCN Myeloid Growth

Full access

Martha Wadleigh and Richard M. Stone

Myeloid growth factors granulocyte-colony stimulating and granulocyte macrophage colony-stimulating factors have been extensively studied in acute leukemias. Whether administered before, during, or after chemotherapy for acute myeloid leukemia and acute lymphoblastic leukemia, these agents reduce the duration of neutropenia and seem to be safe and well tolerated. Despite consistently showing a shorter duration of neutropenia, multiple, prospective, randomized trials have documented only modest benefits in terms of reduction in the incidence and severity of infections, without substantial gains or impact in complete remission, overall survival, and disease-free survival rates. Growth factors have also been used to recruit quiescent leukemia cells into the S-phase of the cell cycle to increase their susceptibility to chemotherapy with the goal to reduce relapse and resistance. Randomized trials evaluating this priming strategy have consistently shown improvement in disease- or event-free survival in the intermediate-risk group of patients with acute myeloid leukemia, but no overall survival benefit. This article focuses on the clinical experience with these agents as adjuncts to the treatment of acute leukemias.

Full access

Gary H. Lyman

. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors in Cancer Treatment. Version 2.2005. Available at: www. nccn.org . Accessed June 2005 . 24 Bodey GP Buckley M Sathe YS . Quantitative relationships between circulating

Full access

David C. Dale

myeloid growth factor guidelines in patients receiving cancer chemotherapy . J Natl Compr Canc Netw 2007 ; 5 : 217 – 228 . 18 Gaberc-Porekar V Zore I Podobnik B Menart V . Obstacles and pitfalls in the PEGylation of therapeutic proteins

Full access

Gary H. Lyman and David C. Dale

EORTC recommend myeloid growth factors be considered for patients undergoing chemotherapy who have a 20% or greater risk of febrile neutropenia. 3 – 5 G-CSF support is closely correlated with the delivery of systemic chemotherapy and, therefore, both